According to Fortune Business Insights, the U.S. allergy immunotherapy market size was worth USD 254.0 million in 2023 and is projected to grow at a CAGR of 10.4% during the forecast period.
Allergy immunotherapy is a treatment approach designed to reduce sensitivity to specific allergens by gradually exposing patients to controlled amounts of substances that trigger allergic reactions. It is commonly used to manage conditions such as allergic rhinitis, allergic asthma associated with specific allergens, and insect venom allergies. The treatment is available primarily through subcutaneous immunotherapy, which involves injections, and sublingual immunotherapy, which involves placing prescribed allergen extracts under the tongue. The U.S. allergy immunotherapy market is gaining attention as awareness of allergic diseases increases and patients seek treatments that address the underlying allergic response rather than providing temporary symptom relief alone. Advances in allergen extracts, improved treatment protocols, and growing interest in personalized allergy care are contributing to market development. Healthcare providers, pharmaceutical companies, and allergy specialists are focusing on improving treatment accessibility, patient adherence, and clinical outcomes.
Continue reading for more details:
https://www.fortunebusinessinsights.com/u-s-allergy-immunotherapy-market-108966
The U.S. allergy immunotherapy market can be segmented by treatment type, allergy type, and distribution channel. By treatment type, the market includes subcutaneous immunotherapy and sublingual immunotherapy. Subcutaneous immunotherapy involves administering allergen extracts through injections under medical supervision. It is widely used for patients with selected environmental allergies and may be recommended when symptoms remain difficult to manage with conventional treatments. This approach requires regular clinical visits during treatment, making healthcare provider availability and patient convenience important factors.
Sublingual immunotherapy involves administering allergen products under the tongue, generally in the form of tablets or prescribed drops, depending on the product and its approved use. It offers a treatment option that can reduce the need for frequent clinic visits after appropriate medical assessment and initiation. Approved sublingual products target specific allergens, and their suitability depends on the patient's allergy profile, medical history, and treatment recommendations. Growing interest in convenient treatment approaches is supporting awareness of sublingual immunotherapy.
By allergy type, the market includes allergic rhinitis, allergic asthma associated with relevant allergens, insect venom allergies, and other allergic conditions for which immunotherapy may be appropriate. Allergic rhinitis is an important application because exposure to pollen, dust mites, and other environmental allergens can cause persistent symptoms. Immunotherapy may help eligible patients develop greater tolerance to specific allergens. Insect venom immunotherapy is used for patients with certain serious allergic reactions to insect stings and requires specialist evaluation.
By distribution channel, the market includes hospital pharmacies, retail pharmacies, specialty pharmacies, and other healthcare distribution channels. Hospitals and allergy clinics play an important role in treatment assessment, administration, and monitoring, particularly for injectable therapies. Retail and specialty pharmacies support access to prescribed products, including eligible sublingual treatments. Distribution patterns depend on product requirements, insurance coverage, prescribing practices, and patient preferences.
The U.S. allergy immunotherapy market is supported by increasing awareness of allergic diseases and growing demand for treatments that provide sustained symptom control. Environmental allergens, including pollen, dust mites, and animal dander, can affect daily activities, sleep quality, and overall well-being. Patients experiencing persistent symptoms may consider immunotherapy when conventional medications do not provide sufficient relief. This creates opportunities for healthcare providers and pharmaceutical companies offering allergen-specific treatment options.
Advancements in allergy diagnosis are contributing to market development. Skin prick tests, blood-based allergy tests, and clinical evaluations help healthcare professionals identify relevant allergens and determine whether patients may benefit from immunotherapy. More targeted diagnosis can support personalized treatment planning and improve the selection of appropriate allergen products. Growing awareness among patients and clinicians about the potential long-term benefits of immunotherapy is also encouraging consideration of these treatments.